Intellia Therapeutics Inc. (NTLA): Among Cathie Wood’s Top Stock Picks for 2025
We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...
Did Intellia Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- NTLA
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia ...
Lost Money on Intellia Therapeutics, Inc.(NTLA)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia ...
Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Lowered by Morgan Stanley
Morgan Stanley lowered shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) from an overweight rating to an equal ...
Fintel on MSN10d
Morgan Stanley Downgrades Intellia Therapeutics (NTLA)
Fintel reports that on January 27, 2025, Morgan Stanley downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 449.14% ...
How Is The Market Feeling About Intellia Therapeutics?
Intellia Therapeutics's NTLA short percent of float has risen 11.06% since its last report. The company recently reported ...
Intellia downgraded at Morgan Stanley on lowered expectations for rare disease asset
Intellia downgraded to market perform at Morgan Stanley on concerns for ATTR-CM candidate nexiguran ziclumeran. Read more ...